Enjamb Labs
ActiveFull stack AI Agents accelerating Biopharma R&D
This company has previously operated under “Enjamb Labs Inc”, “Enjamb”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
Enjamb puts agents across the entire drug program, from preclinical research through clinical trials and approval. Our agents synthesize up-to-date clinical evidence from the literature and real-world data to pinpoint the right endpoints and patient populations; draft and audit regulatory documents like INDs, protocols, SAPs, and NDAs; and run the statistical programming behind them, including SDTM, ADaM, TFLs, and QC, all in one auditable workspace that cuts months off the path from preclinical to clinic and clinic to market.
Founders · 2
Maadhav Deekshitha is an ML researcher working at the intersection of AI and high-performance computing. He was the youngest person to work at the AI Innovation Lab at Dell Technologies, where he developed machine learning models on top of supercomputing infrastructure. He also became one of the youngest contributors in R&D at Broadcom, working on state-of-the-art ASIC systems.
Rayan is an ML and neuroscience researcher who has published first-authored papers and presented at premier conferences, including SOT and the International Society for Computational Biology. His neuroscience work spans five academic labs across UF and FIU, where he focused on developing therapeutics for pesticide poisoning. He also developed DeepImmunoGene, an ML framework for detecting lung cancer immunotherapy biomarkers that outperforms SOTA by 20%.
Related startups
Agent Platform for Life Sciences
Agents that accelerate clinical trials.
